Right to Cross-Reference Clause Samples
The Right to Cross-Reference clause grants parties the ability to refer to other sections, documents, or agreements within the main contract. In practice, this means that obligations, definitions, or procedures outlined elsewhere can be incorporated by reference, streamlining the contract and avoiding unnecessary repetition. This clause ensures consistency and clarity throughout the agreement by allowing related provisions to be linked, reducing ambiguity and the risk of conflicting terms.
POPULAR SAMPLE Copied 1 times
Right to Cross-Reference. In connection with the rights granted pursuant to this Article 3, King agrees that Core may cross-reference the NDA as may be required by Law or as necessary for Core to Manufacture or Commercialize Authorized Generic Product in accordance with customary industry practice. Core may reference the trademark “Skelaxin®” in its advertising to the limited extent of identifying Authorized Generic Product as a generic version of the Branded Product, and shall at all such times that it so uses the trademark “Skelaxin®” identify “Skelaxin®” as a trademark owned by King.
Right to Cross-Reference. Each Party shall have the right to cross-reference and make any other use of the other Party’s NDAs/▇▇▇▇ and INDs/CTAs for the Product that it would have if it were the owner [***] including without limitation access to all data Controlled by the other Party and contained or referenced in such NDAs/▇▇▇▇ and INDs/CTAs, in each case as may be reasonably necessary to enable such Party to Develop, Manufacture or Commercialize Products as permitted under this Agreement. In addition, each Party shall have the right to cross-reference the other Party’s drug master file (“DMF”) in connection with the performance of its obligations under this Agreement.
Right to Cross-Reference. Each Party shall have the right to reference Regulatory Materials of any product comprising the Compound to the extent that such Regulatory Materials are Controlled by the other Party for purposes relating to obtaining Regulatory Approval for a product comprising the Compound. This covenant shall extend to Affiliates and Sublicensees of a Party.
Right to Cross-Reference. Patheon hereby grants to Client, in connection with any Product and any intermediates, components, or derivatives of Product, a perpetual, irrevocable right to cross-reference Patheon’s regulatory submissions and Facility approvals for the purpose of obtaining and maintaining regulatory approvals with respect to the foregoing anywhere in the world. Within [***] weeks after Client’s written request, Patheon shall deliver to Client for filing with the U.S. Food and Drug Administration or any foreign Regulatory Authority designated by Client, such authorization letters as Client reasonably deems necessary for the foregoing purpose [***], subject to such modifications as may be required by Applicable Law; provided, however, that if Customer proposes any material modifications to such form, Patheon shall be entitled to [***]; and provided, further, that Client shall be responsible for all reasonable costs and expenses associated with its request for such cross reference, and for obtaining any notarization, legalization or apostille that may be required for filing any authorization letter with any foreign Regulatory Authority. For the avoidance of doubt, Patheon shall not be required to provide directly to Client any Patheon documents that are generally applicable to Patheon’s business, such as Facility and equipment SOPs unless such documents are expressly requested by a relevant Regulatory Authority or are required by Applicable Law.
Right to Cross-Reference. Subject to obligations of confidentiality in ARTICLE 10, each of ▇▇▇▇▇▇ and Thera Europe may consult with each other and each of them shall share its expertise and Know-How relating to or useful for Regulatory Filings to facilitate the preparation of any Regulatory Filing related to the Initial Product, each Elected Additional Product and any New Presentation. ▇▇▇▇▇▇ hereby grants to Theratechnologies and Thera Europe (and, in the event of MA Transfer, the Thera Transferee) the right to access, cross-reference or use any portion of the Regulatory Filings or Marketing Authorisations for the Initial Product (a) to Commercialize, either themselves or through their Affiliates or any Third Party, (i) the Initial Product outside the Territory, and (ii) any Additional Product within or outside the Territory; (b) to conduct any Development activities within or outside the Territory, related to (i) any Product (including Clinical Trials, Phase IV Trials and New Presentations) and/or (ii) any Additional Product, and (c) to make and have made the Initial Product, any Elected Additional Product, and/or New Presentation in each case within or outside the Territory.
Right to Cross-Reference. Brammer hereby grants to Customer, its Affiliates and its sublicensees, with respect to the Product, a perpetual, irrevocable, sublicensable right to cross-reference ▇▇▇▇▇▇▇’▇ regulatory submissions and Facility approvals for the purpose of obtaining and maintaining Regulatory Approvals with respect to the Product anywhere in the world. Within [**] after Customer’s written request, Brammer shall deliver to Customer for filing with the FDA or any foreign Regulatory Authority designated by Customer such authorization letters as Customer reasonably deems necessary for the foregoing purpose, which shall be substantially in the form attached hereto as Appendix B, subject to such modifications as may be required by Applicable Laws; provided, however, that if Customer proposes any material modifications to such form, Brammer shall be entitled to an additional [**] for review and approval of the modified form; and provided, further, that [**] associated with its request for such cross-reference, and for obtaining any notarization, legalization or apostille that may be required for filing any authorization letter with any foreign Regulatory Authority. For the avoidance of doubt, Brammer shall not be required to provide directly to Customer any Brammer documents that are general to ▇▇▇▇▇▇▇’▇ business, such as Facility and equipment SOPs unless such documents are necessary to obtain any Regulatory Approvals with respect to the Product.
Right to Cross-Reference. Brammer hereby grants to Customer, its Affiliates and its sublicensees, with respect to a Product, a perpetual, irrevocable right to cross-reference ▇▇▇▇▇▇▇’▇ regulatory submissions and Facility approvals for the purpose of obtaining and maintaining regulatory approvals (including Regulatory Approvals) with respect to each Product anywhere in the world. Within [**] after Customer’s written request, Brammer shall deliver to Customer for filing with the FDA or any foreign Regulatory Authority designated by Customer such authorization letters as Customer reasonably deems necessary for the foregoing purpose, which shall be substantially in the form attached hereto as Appendix B, subject to such modifications as may be required by Applicable Laws; provided, however, that if Customer proposes any material modifications ActiveUS 170335185 to such form, Brammer shall be entitled to an additional [**] for review and approval of the modified form; and provided, further, that Customer shall be responsible for all costs and expenses associated with its request for such cross-reference, and for obtaining any notarization, legalization or apostille that may be required for filing any authorization letter with any foreign Regulatory Authority. For the avoidance of doubt, Brammer shall not be required to provide directly to Customer any Brammer documents that are general to ▇▇▇▇▇▇▇’▇ business, such as a Facility and equipment SOPs unless such documents are expressly requested by a relevant Regulatory Authority or are required by Applicable Laws. Additionally, if required, at Customer’s request and cost, Brammer shall promptly provide Customer with copies of all granted Regulatory Approvals and any other permits related to the manufacture of any Product. Customer will have the right to use any and all information contained in such approvals in connection with its own applications for Regulatory Approval and/or commercial development of the Products.
Right to Cross-Reference. Subject to obligations of confidentiality in Article 11, each Party may consult with the other Party and each Party shall share its expertise and Know-How relating to or useful for Regulatory Filings to facilitate the preparation of any Regulatory Filings related to the Product. As holder of the Marketing Authorisation under license from Thera, SA hereby grants to Thera the right to access, cross-reference or use any portion of the Regulatory Filings or Marketing Authorisation of the Product. SA shall provide Thera, if requested by Thera and within a reasonable period of time as of such request, with all documentation relating to any variation to the Regulatory Filings approved by the Regulatory Authorities.
Right to Cross-Reference. Each Party shall have the right to cross-reference and make any other use of the other Party’s Regulatory Documentation for the Product that it would have if it were the owner, including without limitation access to all data contained or referenced in such Regulatory Documentation, in each case as may be reasonably necessary to enable such Party to develop, Manufacture or commercialize the Product; except that such right of cross-reference and use shall not apply to trials pursued independently by one Party pursuant to Sections 5.4 or 5.5.